암 생검 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 유형별, 용도별, 지역별, 부문별 예측(2024-2030년)

Cancer Biopsy Market Growth & Trends:

The global cancer biopsy market size is expected to reach USD 51.61 billion by 2030, registering a CAGR of 8.11% from 2024 to 2030, according to a new report by Grand View Research, Inc. The advancement in molecular medicine has facilitated the creation of novel devices for the molecular characterization of cancers. As a result, the rising acceptance and approvals of liquid biopsies are anticipated to be significant driving forces behind the overall market growth.

Numerous emerging manufacturers are dedicated to developing instruments that can improve endoscopy-based cancer biopsies. For instance, in March 2023, BiBBInstruments AB, a Swedish company, established a strong presence in the cancer biopsy instruments market under the brand - EndoDrill. The company changed biopsy instruments that allow rapid and precise diagnosis of cancer patients related to existing biopsy instruments. Moreover, it offers biopsy instruments catering to core needles and flexible endoscopic biopsies. Such companies developing in the market are expected to upsurge the accessibility of cancer biopsy instruments.

The field of oncology-based genomic data analysis and personalized medicine is anticipated to witness lucrative prospects with the emergence of liquid biopsies. Regulatory bodies are actively backing the commercialization of these products and promoting their utilization in clinical settings due to the significant potential they offer. Liquid biopsy facilitates cancer detection through various body fluids, and the advancements in this technique have made it an appealing noninvasive approach for obtaining cancer biomaterials for diagnostic purposes.

The liquid biopsies segment is projected to experience rapid expansion in the upcoming years, driven by significant investments and strategic efforts from companies engaged in biopharmaceutical manufacturing and genomic data analysis. Emerging companies are showing a strong inclination towards forming partnerships with established industry participants like QIAGEN Bioinformatics, Fabric Genomics, Agilent Technologies, and SOPHiA Genetics. This collaborative trend is expected to further boost the overall market growth.

Cancer Biopsy Market Report Highlights:

• In 2023, kits and consumables held the largest market share by product, and this dominance is projected to persist throughout the forecast period. The increased adoption of kits and consumables can be attributed to the notable shift from tumor biopsies to liquid biopsies.
• Tissue biopsies remain a fundamental aspect of the biopsy process and are widely utilized across various diagnostic applications. Furthermore, tumor biopsies are primarily employed for individual-level diagnosis and monitoring the efficacy of ongoing oncology treatments.
• In terms of application, breast cancer dominated the global market in 2023 and is expected to maintain its lead throughout the forecast period. Open surgical biopsy remains a reference standard for evaluating patients with suspicious breast lesions, owing to its established accuracy in diagnosing such conditions. Consequently, this segment's revenue is bolstered by its proven efficacy in breast lesion diagnosis.
• North America held the largest revenue share in 2023 owing to the concentrated pool of active organizations and cancer foundations. The strong network of government organizations and private cancer foundations in the U.S. has made significant contributions to the regional revenue generation capacity.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product and type outlook
  • 2.2.2. Application outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cancer Biopsy Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advent of liquid biopsy
    • 3.2.1.2. Transition of novel oncology diagnostics from bench to clinics
    • 3.2.1.3. Advancements in quality and payment pertaining to genetic cancer tests
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Risks associated with biopsy procedures
    • 3.2.2.2. Technical and clinical challenges
• 3.3. Cancer Biopsy Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Cancer Biopsy Market: Product Estimates & Trend Analysis

• 4.1. Global Cancer Biopsy Market: Product Dashboard
• 4.2. Global Cancer Biopsy Market: Product Movement Analysis
• 4.3. Global Cancer Biopsy Market by Product, Revenue
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.5. Kits and Consumables
  • 4.5.1. Kits and consumables market estimates and forecasts 2018 to 2030 (USD Billion)
• 4.6. Services
  • 4.6.1. Services market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Cancer Biopsy Market: Type Estimates & Trend Analysis

• 5.1. Global Cancer Biopsy Market: Type Dashboard
• 5.2. Global Cancer Biopsy Market: Type Movement Analysis
• 5.3. Global Cancer Biopsy Market by Type, Revenue
• 5.4. Tissue Biopsies
  • 5.4.1. Tissue biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.2. Needle Biopsies
  • 5.4.3. Needle biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.4. Fine Needle Aspiration (FNA)
    • 5.4.4.1. Fine Needle Aspiration (FNA) market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.5. Core Needle Biopsy (CNB)
    • 5.4.5.1. Core Needle Biopsy (CNB) market estimates and forecasts 2018 to 2030 (USD Billion)
  • 5.4.6. Surgical Biopsies
  • 5.4.7. Surgical biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.5. Liquid Biopsies
  • 5.5.1. Liquid biopsies market estimates and forecasts 2018 to 2030 (USD Billion)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Cancer Biopsy Market: Application Estimates & Trend Analysis

• 6.1. Global Cancer Biopsy Market: Application Dashboard
• 6.2. Global Cancer Biopsy Market: Application Movement Analysis
• 6.3. Global Cancer Biopsy Market by Application, Revenue
• 6.4. Breast Cancer
  • 6.4.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Colorectal Cancer
  • 6.5.1. Colorectal cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Cervical Cancer
  • 6.6.1. Cervical cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. Lung Cancer
  • 6.7.1. Lung cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.8. Prostate Cancer
  • 6.8.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.9. Skin Cancer
  • 6.9.1. Skin cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.10. Blood Cancer
  • 6.10.1. Blood cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.11. Kidney Cancer
  • 6.11.1. Kidney cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.12. Liver Cancer
  • 6.12.1. Liver cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.13. Pancreatic Cancer
  • 6.13.1. Pancreatic cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.14. Ovarian Cancer
  • 6.14.1. Ovarian cancer market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.15. Others
  • 6.15.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Cancer Biopsy Market: Regional Estimates & Trend Analysis by Type, Tube Material, Application, and End-use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. QIAGEN
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Illumina, Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. ANGLE plc
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. BD (Becton, Dickinson and Company)
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Myriad Genetics, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Hologic, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Biocept, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Thermo Fisher Scientific, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Danaher
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. F. Hoffmann-La Roche Ltd.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Lucence Health Inc.
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. GRAIL, Inc.
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives
  • 8.3.16. Guardant Health Inc.
    • 8.3.16.1. Company overview
    • 8.3.16.2. Financial performance
    • 8.3.16.3. Product benchmarking
    • 8.3.16.4. Strategic initiatives
  • 8.3.17. Exact Sciences Corporation
    • 8.3.17.1. Company overview
    • 8.3.17.2. Financial performance
    • 8.3.17.3. Product benchmarking
    • 8.3.17.4. Strategic initiatives
  • 8.3.18. Freenome Holdings, Inc.
    • 8.3.18.1. Company overview
    • 8.3.18.2. Financial performance
    • 8.3.18.3. Product benchmarking
    • 8.3.18.4. Strategic initiatives
  • 8.3.19. Biodesix (Integrated Diagnostics)
    • 8.3.19.1. Company overview
    • 8.3.19.2. Financial performance
    • 8.3.19.3. Product benchmarking
    • 8.3.19.4. Strategic initiatives
  • 8.3.20. Oncimmune
    • 8.3.20.1. Company overview
    • 8.3.20.2. Financial performance
    • 8.3.20.3. Product benchmarking
    • 8.3.20.4. Strategic initiatives
  • 8.3.21. Epigenomics AG
    • 8.3.21.1. Company overview
    • 8.3.21.2. Financial performance
    • 8.3.21.3. Product benchmarking
    • 8.3.21.4. Strategic initiatives
  • 8.3.22. HelioHealth (Laboratory for Advanced Medicine)
    • 8.3.22.1. Company overview
    • 8.3.22.2. Financial performance
    • 8.3.22.3. Product benchmarking
    • 8.3.22.4. Strategic initiatives
  • 8.3.23. Genesystems, Inc. (Genesys Biolabs)
    • 8.3.23.1. Company overview
    • 8.3.23.2. Financial performance
    • 8.3.23.3. Product benchmarking
    • 8.3.23.4. Strategic initiatives
  • 8.3.24. Chronix Biomedical, Inc.
    • 8.3.24.1. Company overview
    • 8.3.24.2. Financial performance
    • 8.3.24.3. Product benchmarking
    • 8.3.24.4. Strategic initiatives
  • 8.3.25. Personal Genome Diagnostics Inc.
    • 8.3.25.1. Company overview
    • 8.3.25.2. Financial performance
    • 8.3.25.3. Product benchmarking
    • 8.3.25.4. Strategic initiatives
  • 8.3.26. Natera, Inc.
    • 8.3.26.1. Company overview
    • 8.3.26.2. Financial performance
    • 8.3.26.3. Product benchmarking
    • 8.3.26.4. Strategic initiatives
  • 8.3.27. Personalis Inc.
    • 8.3.27.1. Company overview
    • 8.3.27.2. Financial performance
    • 8.3.27.3. Product benchmarking
    • 8.3.27.4. Strategic initiatives